Background Biochemical recurrence (BCR) following primary interventional treatment
occurs in approximately one-third of patients with prostate cancer (PCa). Next-generation …

Biochemical recurrence (BCR) occurs in 20–50% of patients with prostate cancer (PCa)
undergoing primary definitive treatment. Patients with high-risk BCR have an increased risk …

The European Association of Urology (EAU) prostate cancer guidelines panel recommends
risk groups for biochemical recurrence (BCR) of prostate cancer to identify men at high risk …

Abstract Objective To assess European Association of Urology (EAU) risk groups for
biochemical recurrence (BCR) of prostate cancer relative to prostate‐specific membrane …

Simple Summary Prostate specific membrane antigen (PSMA) is a transmembrane protein
that is highly expressed in prostate cancer cells. For patients with metastatic castration …

Prostate cancer (PCa) has become a public health concern in elderly men due to an ever‐
increasing number of estimated cases. Unfortunately, the available treatments are …

Simple Summary The risk of early progression to metastatic disease in the event of
biochemical recurrence (BCR) after primary treatment for prostate cancer (PC) is extremely …

Simple Summary In prostate cancer patients with low-volume/oligo-metastatic relapse after
radical prostatectomy, radioguided surgery against prostate-specific membrane antigen …

Simple Summary After radical prostatectomy (RP), about a third of patients present with
BCR. The European Association of Urology (EAU) biochemical recurrence (BCR) risk …

Background Salvage radiation therapy (SRT) and surveillance for low‐risk prostate‐specific
antigen (PSA) recurrence have competing risks and benefits. The efficacy of early SRT to the …